Trial Profile
A Phase 1 Food Effect Study of BMN 673 Administered to Healthy Adult Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Pharmacokinetics
- Sponsors BioMarin Pharmaceutical
- 21 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research.
- 03 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.